Département de Radio-Oncologie, Centre hospitalier universitaire de Québec, Québec, Québec G1R 2J6, Canada.
Med Phys. 2012 Oct;39(10):6208-36. doi: 10.1118/1.4747264.
The charge of Task Group 186 (TG-186) is to provide guidance for early adopters of model-based dose calculation algorithms (MBDCAs) for brachytherapy (BT) dose calculations to ensure practice uniformity. Contrary to external beam radiotherapy, heterogeneity correction algorithms have only recently been made available to the BT community. Yet, BT dose calculation accuracy is highly dependent on scatter conditions and photoelectric effect cross-sections relative to water. In specific situations, differences between the current water-based BT dose calculation formalism (TG-43) and MBDCAs can lead to differences in calculated doses exceeding a factor of 10. MBDCAs raise three major issues that are not addressed by current guidance documents: (1) MBDCA calculated doses are sensitive to the dose specification medium, resulting in energy-dependent differences between dose calculated to water in a homogeneous water geometry (TG-43), dose calculated to the local medium in the heterogeneous medium, and the intermediate scenario of dose calculated to a small volume of water in the heterogeneous medium. (2) MBDCA doses are sensitive to voxel-by-voxel interaction cross sections. Neither conventional single-energy CT nor ICRU∕ICRP tissue composition compilations provide useful guidance for the task of assigning interaction cross sections to each voxel. (3) Since each patient-source-applicator combination is unique, having reference data for each possible combination to benchmark MBDCAs is an impractical strategy. Hence, a new commissioning process is required. TG-186 addresses in detail the above issues through the literature review and provides explicit recommendations based on the current state of knowledge. TG-43-based dose prescription and dose calculation remain in effect, with MBDCA dose reporting performed in parallel when available. In using MBDCAs, it is recommended that the radiation transport should be performed in the heterogeneous medium and, at minimum, the dose to the local medium be reported along with the TG-43 calculated doses. Assignments of voxel-by-voxel cross sections represent a particular challenge. Electron density information is readily extracted from CT imaging, but cannot be used to distinguish between different materials having the same density. Therefore, a recommendation is made to use a number of standardized materials to maintain uniformity across institutions. Sensitivity analysis shows that this recommendation offers increased accuracy over TG-43. MBDCA commissioning will share commonalities with current TG-43-based systems, but in addition there will be algorithm-specific tasks. Two levels of commissioning are recommended: reproducing TG-43 dose parameters and testing the advanced capabilities of MBDCAs. For validation of heterogeneity and scatter conditions, MBDCAs should mimic the 3D dose distributions from reference virtual geometries. Potential changes in BT dose prescriptions and MBDCA limitations are discussed. When data required for full MBDCA implementation are insufficient, interim recommendations are made and potential areas of research are identified. Application of TG-186 guidance should retain practice uniformity in transitioning from the TG-43 to the MBDCA approach.
任务组 186(TG-186)的职责是为早期采用基于模型的剂量计算算法(MBDCA)进行近距离治疗(BT)剂量计算的人员提供指导,以确保实践的一致性。与外部束放射治疗不同,最近才向 BT 界提供了不均匀性校正算法。然而,BT 剂量计算的准确性高度依赖于散射条件和光电效应相对于水的截面。在特定情况下,当前基于水的 BT 剂量计算形式(TG-43)和 MBDCA 之间的差异可能导致计算剂量的差异超过 10 倍。MBDCA 提出了三个当前指南文件未涉及的主要问题:(1)MBDCA 计算的剂量对剂量规范介质敏感,导致在同质水几何形状中计算到水的剂量(TG-43)、计算到不均匀介质中的局部介质的剂量以及在不均匀介质中的小体积水的中间情况下计算到的剂量之间存在能量依赖性差异。(2)MBDCA 剂量对体素对体素相互作用截面敏感。常规的单能 CT 或 ICRU/ICRP 组织成分汇编都不能为为每个体素分配相互作用截面提供有用的指导。(3)由于每个患者-源-施源器组合都是唯一的,因此为每个可能的组合提供参考数据以基准 MBDCA 是不切实际的策略。因此,需要一个新的调试过程。TG-186 通过文献回顾详细讨论了上述问题,并根据当前的知识状况提供了明确的建议。基于 TG-43 的剂量处方和剂量计算仍然有效,当可用时,以并行方式报告 MBDCA 剂量。在使用 MBDCA 时,建议在不均匀介质中进行辐射传输,并且至少应报告局部介质的剂量以及 TG-43 计算的剂量。体素对体素截面的分配是一个特殊的挑战。电子密度信息可从 CT 成像中轻松提取,但不能用于区分具有相同密度的不同材料。因此,建议使用多种标准化材料来保持机构之间的一致性。敏感性分析表明,与 TG-43 相比,该建议可提高准确性。MBDCA 的调试将与当前基于 TG-43 的系统具有共同性,但除此之外,还有特定于算法的任务。建议进行两个级别的调试:复制 TG-43 剂量参数和测试 MBDCA 的高级功能。为了验证不均匀性和散射条件,MBDCA 应模拟参考虚拟几何形状的 3D 剂量分布。讨论了 BT 剂量处方的潜在变化和 MBDCA 的局限性。当完全实施 MBDCA 所需的数据不足时,将提出临时建议并确定潜在的研究领域。应用 TG-186 指南应在从 TG-43 向 MBDCA 方法过渡时保持实践的一致性。